TICKERNERD
Menu
ALLOALLOHealthcare · Biotechnology

ALLO Stock Forecast: Allogene Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$1.18
−5.60% on the day

The 12 Wall Street analysts covering Allogene Therapeutics, Inc. hold a median 12-month price target of $9 — +662.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 31 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$407.7M
Ticker Nerd rank
74/ 100
Median analyst target
$9.00
Analysts covering
12
Revenue$4.6M
Operating income−$46.9M
Net income−$42.7M
Free cash flow−$32.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.6%
1M
−26.3%
YTD
−13.9%
1Y
−2.5%
From 52W high
−61.4%
From 52W low
+12.4%
$1.05
$3.06
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALLO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Allogene Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
74/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
77
Revisions
74
Growth
69
Accruals
65
Size
56
Momentum
53
Volatility
49
Value
47
Issuance
46

Quality (77): The business earns solid, repeatable profits on what it owns.

Issuance (46): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ALLO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALLO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26ALLOHigh $14.00Median $9.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
11 Buy1 Hold0 Sell
Low $4.00Median $9.00High $14.00

The green dot is the last close — the median target sits +662.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
17 Aug 2026CitizensReiteratesMarket Outperform$6.00
16 Apr 2026HC Wainwright & Co.MaintainsBuy$12 → $11
16 Apr 2026HC Wainwright & Co.MaintainsBuy—
16 Apr 2026JP MorganUpgradeNeutral—
16 Apr 2026JP MorganUpgradeNeutral—
15 Apr 2026JefferiesMaintainsBuy$6.00 → $10
15 Apr 2026JefferiesMaintainsBuy—
14 Apr 2026Argus ResearchMaintainsMarket Perform—
14 Apr 2026Argus ResearchMaintainsMarket Perform$1.60 → $3.85
14 Apr 2026BairdMaintainsOutperform$7.00 → $9.00
14 Apr 2026BairdMaintainsOutperform—
14 Apr 2026BernsteinMaintainsMarket Perform—
14 Apr 2026BernsteinMaintainsMarket Perform$1.60 → $3.85
14 Apr 2026CitizensMaintainsMarket Outperform$5.00 → $8.00
14 Apr 2026CitizensMaintainsMarket Outperform—
14 Apr 2026HC Wainwright & Co.MaintainsBuy$8.00 → $12
14 Apr 2026HC Wainwright & Co.MaintainsBuy—
13 Mar 2026Canaccord GenuityMaintainsBuy—
13 Mar 2026Piper SandlerMaintainsOverweight—
9 Jan 2026CitizensUpgradeMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ALLO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ALLO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Allogene Therapeutics, Inc. returned −2.5% against +12.4% for the S&P 500, dividends included.

ALLO vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Jan 26Apr 26Jul 26Oct 26ALLOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALLO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Allogene Therapeutics, Inc. (ALLO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.3×

Cheaper than 85% of US stocks

Price / sales
87.9×

Cheaper than 4% of US stocks

Price / book
0.9×

Cheaper than 72% of US stocks

EV / EBITDA
−0.9×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−1011.2%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−42.4%

Higher than 24% of US stocks

Return on assets
−22.1%

Higher than 18% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Allogene Therapeutics, Inc. (ALLO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Allogene Therapeutics, Inc. has a market value of $407.7M and an enterprise value of $154.1M.

  • Revenue in the twelve months to 30 June 2026: $4.6M.

  • Net income over the same four quarters: −$165.5M, a −3566.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.67.

  • Free cash flow in the twelve months to 30 June 2026: −$102.6M.

  • Shares outstanding: 345.3M.

  • Trailing P/E: −1.3×; forward P/E: −1.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Allogene Therapeutics, Inc. employs 150 people — $31K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

ALLO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALLOAllogene Therapeutics, Inc.$407.7M74
PROKProKidney Corp.$390.8M38
ALTAltimmune, Inc.$396.5M29
ZURAZura Bio Ltd.$383.3M31
ASMBAssembly Biosciences, Inc.$398.9M78
RZLTRezolute, Inc.$378.0M37
AVTXAvalo Therapeutics, Inc.$376.9M27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Allogene Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALLO news & analysis

Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data

GlobeNewsWire · 29 Oct 2026neutral

Allogene Therapeutics announced two November investor events that will highlight its third-quarter 2026 results and provide the first clinical update from its ALLO-329 autoimmune disease program.

Why it matters — The events are an opportunity for ALLO watchers to hear the company’s quarterly results and initial clinical information on ALLO-329.

Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?

Zacks Investment Research · 11 Sept 2026neutral

Allogene Therapeutics reported earnings 30 days ago, and its stock has declined 11.1% since that report. The article raises the question of whether the stock can rebound.

Why it matters — Investors following ALLO would care about how the stock has performed since the latest earnings report and whether it may recover.

Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 9 Sept 2026neutral

Allogene Therapeutics presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation published by Seeking Alpha. The item reports on the company's participation in the investor conference.

Why it matters — An ALLO watcher would care because the presentation gives investors an opportunity to hear directly from the company's leadership about its business and strategy.

Stock Picks From Seeking Alpha's August 2026 New Analysts

Seeking Alpha · 8 Sept 2026positive

Seeking Alpha welcomed 25 new analysts in August, showcasing their stock picks and investment strategies with ratings ranging from Strong Sell to Strong Buy. Allogene Therapeutics was highlighted among the key bullish investment theses presented by these analysts.

Why it matters — A ALLO watcher would care because Allogene Therapeutics was featured as one of the bullish stock picks among Seeking Alpha's newly added analysts.

FAQ

Frequently asked questions about ALLO stock

What is the ALLO stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Allogene Therapeutics, Inc. have a median 12-month price target of $9, with estimates ranging from $4 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALLO stock a buy right now?

Of the 12 analysts covering Allogene Therapeutics, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Allogene Therapeutics, Inc. 74 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALLO?

As at 31 Oct 2026, Allogene Therapeutics, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (77 of 100).

Will ALLO stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +662.7% from the last close, and Ticker Nerd's factor model ranks Allogene Therapeutics, Inc. 74 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALLO stock forecast for 2030?

No analyst covering Allogene Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALLO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $14 over the next 12 months.

How has ALLO stock performed over the past year?

Allogene Therapeutics, Inc. returned -2.5% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Allogene Therapeutics, Inc. do?

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or donor-derived, CAR T cell therapies for cancer and autoimmune disease.

What is the latest news on ALLO?

The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data". Allogene Therapeutics announced two November investor events that will highlight its third-quarter 2026 results and provide the first clinical update from its ALLO-329 autoimmune disease program.

Company

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or donor-derived, CAR T cell therapies for cancer and autoimmune disease. The company’s current work centers on investigational off-the-shelf cell therapy candidates designed to be manufactured from healthy donor cells and delivered more readily to patients than individualized treatments. Its pipeline includes programs targeting blood cancers, solid tumors, and autoimmune disorders, with emphasis on areas such as large B-cell lymphoma, renal cell carcinoma, and other oncology indications. Allogene Therapeutics also develops supporting technologies and manufacturing capabilities that are intended to improve the consistency, scalability, and accessibility of its cell therapy platform. Headquartered in South San Francisco, California, Allogene Therapeutics plays a specialized role in the immuno-oncology market as a developer of next-generation cell therapies for complex diseases.

CEO Dr. Zachary J. Roberts M.D., Ph.D. · 150 employees · United States · https://allogene.com